Abstract Objectives To assess the epidemiology, clinical manifestations and outcome of mucormycosis over 15 years in a single center in France. Material/methods We conducted a retrospective analysis of all mucormycosis cases in our institution from 01/01/2006 to 31/12/2020 and analyzed patients charts, laboratory results and treatment to describe the epidemiology, clinical manifestations, diagnosis, treatment and outcome. Mucorales qPCR for the diagnosis was implemented in 2015. Results Seventy-seven mucormycosis cases were analyzed in 77 patients, with a median age of 54 years, 60% were male. Identified risk factors were hematological diseases (46 cases(60%)), solid malignancies (2 cases), solid organ transplants (3), burns (18), diabetes only (7) and trauma (1). Sites of infection were lungs (42%), sinus (36%), skin (31%), central nervous system (9%), liver (8%), others (6%), disseminated (12%). Diagnosis remained difficult and qPCR contributed to mucormycosis diagnosis in 30% of cases. Among hematology patients, serum qPCR was the only positive test in 15% of cases. A mixed mold infections was diagnosed in 24/77 (31%) patients. Surgical treatment was undertaken in 43 (56%) cases. Most patients received liposomal amphotericin B (89%), with a combination therapy in 18/77 cases (23%). Three-month survival rate was 40% (95%IC: 0.30-0.53). As for treatment, adjunction of surgery (HR: 0.4 (0.2-0.7), p: 0.002) was associated with lower mortality. Conclusions Mucormycosis remained associated with high mortality especially in the hematological and burn population. Surgery in combination with antifungal treatment is associated with improved survival.